Abstract
Conventional treatment of pulmonary arterial hypertension (PAH) includes oxygen supplementation, calcium channel blockers, anticoagulation, digoxin, and diuretics. Calcium channel blockers have little or no effect on the majority of patients with moderate or severe PAH. Apart from the intravenous prostacyclin which remains the gold standard treatment for this life-threatening entity, newer drugs such as prostacyclin analogues, endothelin-receptor antagonists, and phosphodiesterase-5 inhibitors alone or in combination administered by means of different routes have been shown to improve oxygenation, hemodynamics, exercise tolerance, symptoms, and quality of life. Based on current WHO classification there are 5 groups of pulmonary hypertension. In this article, PAH is used exclusively for Group 1 of WHO classification. There are currently six FDA approved therapies for PAH. However, all these therapeutic agents and approaches have not offered yet a cure of PAH. This review article presents the recent advances in the management of PAH.
Keywords: Prostanoids, nitric oxide, endothelin-receptor antagonist, epoprostenol, phosphodiesterase 5 inhibitors
Current Respiratory Medicine Reviews
Title: Recent Advances in the Management of Pulmonary Arterial Hypertension
Volume: 5 Issue: 1
Author(s): Emmanuel Papadakis and Argyris Michalopoulos
Affiliation:
Keywords: Prostanoids, nitric oxide, endothelin-receptor antagonist, epoprostenol, phosphodiesterase 5 inhibitors
Abstract: Conventional treatment of pulmonary arterial hypertension (PAH) includes oxygen supplementation, calcium channel blockers, anticoagulation, digoxin, and diuretics. Calcium channel blockers have little or no effect on the majority of patients with moderate or severe PAH. Apart from the intravenous prostacyclin which remains the gold standard treatment for this life-threatening entity, newer drugs such as prostacyclin analogues, endothelin-receptor antagonists, and phosphodiesterase-5 inhibitors alone or in combination administered by means of different routes have been shown to improve oxygenation, hemodynamics, exercise tolerance, symptoms, and quality of life. Based on current WHO classification there are 5 groups of pulmonary hypertension. In this article, PAH is used exclusively for Group 1 of WHO classification. There are currently six FDA approved therapies for PAH. However, all these therapeutic agents and approaches have not offered yet a cure of PAH. This review article presents the recent advances in the management of PAH.
Export Options
About this article
Cite this article as:
Papadakis Emmanuel and Michalopoulos Argyris, Recent Advances in the Management of Pulmonary Arterial Hypertension, Current Respiratory Medicine Reviews 2009; 5 (1) . https://dx.doi.org/10.2174/157339809787353976
DOI https://dx.doi.org/10.2174/157339809787353976 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Global Safety of Coxibs and NSAIDs
Current Topics in Medicinal Chemistry Investigations Into the Drug-Drug Interaction Potential of Tapentadol in Human Liver Microsomes and Fresh Human Hepatocytes
Drug Metabolism Letters The Relevance of Long-Term Adherence to Non-Pharmacological and Pharmacological Treatment of Hypertension
Current Hypertension Reviews Brain: The Potential Diagnostic and Therapeutic Target for Glaucoma
CNS & Neurological Disorders - Drug Targets Bioorganic Compounds Produced by the Fungus Monascus and their Use in Health Sciences and Medicine
Mini-Reviews in Organic Chemistry Alzheimer’s Disease is Associated with Increased Risk of Osteoporosis: The Chongqing Aging Study
Current Alzheimer Research Salusins in Hypertension and Related Cardiovascular Diseases
Current Drug Metabolism Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Novel Insights into Vascular Repair Mechanisms
Current Pharmaceutical Design Cardiovascular Physiology of Androgens and Androgen Testosterone Therapy in Postmenopausal Women
Endocrine, Metabolic & Immune Disorders - Drug Targets PPAR-γ Agonists in Polycystic Kidney Disease with Frequent Development of Cardiovascular Disorders
Current Molecular Pharmacology Pharmacological and Surgical Therapy for Primary Postpartum Hemorrhage
Current Pharmaceutical Design Roles of CLR/RAMP Receptor Signaling in Reproduction and Development
Current Protein & Peptide Science Should all Hypertensive Patients be Screened for Primary Aldosteronism?
Current Hypertension Reviews Patent Selections
Recent Patents on Biomedical Engineering (Discontinued) Bamboo a Supplement to Human Health: A Comprehensive Review on its Ethnopharmacology, Phytochemistry, and Pharmacological Activity
The Natural Products Journal Epinephrine and its Role in the Development of Obesity and Hypertension
Current Hypertension Reviews Human Umbilical Cord Mesenchymal Stem Cells Therapy for Insulin Resistance: A Novel Strategy in Clinical Implication
Current Stem Cell Research & Therapy Editorial [Hot Topic: Sedation and Analgesia in Post-Anesthesia Intensive Care Unit (Guest Editors: F. Cavaliere and R. Proietti)]
Current Drug Targets Melanogenesis and Melanosome Transportation Modulators from Medicinal Plants
Letters in Drug Design & Discovery